— Academic leader in HTA to rejoin ICER in November 2023 —
September 27, 2023 – In November 2023, Daniel Ollendorf, PhD, MPH will become Chief Scientific Officer and Director of Health Technology Assessment (HTA) Methods and Engagement at the Institute for Clinical and Economic Review (ICER).
From 2007-2018, Dr. Ollendorf was Chief Scientific Officer for ICER, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators. He is currently the Director of Value Measurement & Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, where he focuses on value assessment methods, drug pricing policy, and building international capacity for and interest in HTA.
In addition to his new role at ICER, Dr. Ollendorf will maintain a faculty appointment at CEVR and will continue to teach in the Center’s graduate certificate program as well as participate in ongoing research.
“Dan was one of ICER’s first employees and helped to build much of the foundation for ICER’s ongoing success,” said Sarah Emond, MPP, President-Elect of ICER. “Dan is well-known for his innovative research on HTA methods at CEVR and at ICER. His technical skills, coupled with his ability to build and lead cross-functional teams and his deep connection to international best practices will contribute significantly to our ability to demonstrate how the US health system can evolve towards fair pricing, fair patient access, and continued incentives for future innovation.”
Dr. Ollendorf stated, “I am looking forward to rejoining ICER at a critical time for the US health care system. The foundation we built to evaluate the clinical and economic impact of drugs, devices, and other technologies so patients can access high-value care is as important today as it was when we started decades ago. I am also grateful for my time at CEVR and the opportunity to continue collaborations with colleagues there. I hope to use my understanding of ICER’s role in the larger health policy ecosystem to explore research partnerships with CEVR and other institutions, deepen engagement with stakeholders, and help to realize ICER’s vision for the future.”
Dr. Ollendorf also serves as a non-resident Fellow in Global Health at the Center for Global Development and is the current Chair of the Health Technology Assessment International (HTAi) Global Policy Forum. He received his PhD in Clinical Epidemiology from the University of Amsterdam, and an MPH in Health Policy & Management/Epidemiology from Boston University.
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.